Anti-CD5L/CT-2 antibody,Abcam,AB45406

Host

Rabbit

Reactivity

Human

Application

IHC-P, WB

Platform ID

BAB566128801

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-CD5L/CT-2 antibody
Cat. No.AB45406
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationIHC-P, WB
ClonalityPolyclonal
Concentration1 mg/mL Batch dependent concentration
ImmunogenSynthetic Peptide within Human CD5L. The exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Immunogen
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 Preservative: 0.02% Sodium azide Constituents: PBS
Storage+4°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Secreted protein that acts as a key regulator of lipid synthesis : mainly expressed by macrophages in lymphoid and inflamed tissues and regulates mechanisms in inflammatory responses, such as infection or atherosclerosis. Able to inhibit lipid droplet size in adipocytes. Following incorporation into mature adipocytes via CD36-mediated endocytosis, associates with cytosolic FASN, inhibiting fatty acid synthase activity and leading to lipolysis, the degradation of triacylglycerols into glycerol and free fatty acids (FFA). CD5L-induced lipolysis occurs with progression of obesity : participates in obesity-associated inflammation following recruitment of inflammatory macrophages into adipose tissues, a cause of insulin resistance and obesity-related metabolic disease. Regulation of intracellular lipids mediated by CD5L has a direct effect on transcription regulation mediated by nuclear receptors ROR-gamma (RORC). Acts as a key regulator of metabolic switch in T-helper Th17 cells. Regulates the expression of pro-inflammatory genes in Th17 cells by altering the lipid content and limiting synthesis of cholesterol ligand of RORC, the master transcription factor of Th17-cell differentiation. CD5L is mainly present in non-pathogenic Th17 cells, where it decreases the content of polyunsaturated fatty acyls (PUFA), affecting two metabolic proteins MSMO1 and CYP51A1, which synthesize ligands of RORC, limiting RORC activity and expression of pro-inflammatory genes. Participates in obesity-associated autoimmunity via its association with IgM, interfering with the binding of IgM to Fcalpha/mu receptor and enhancing the development of long-lived plasma cells that produce high-affinity IgG autoantibodies (By similarity). Also acts as an inhibitor of apoptosis in macrophages : promotes macrophage survival from the apoptotic effects of oxidized lipids in case of atherosclerosis (PubMed : 24295828). Involved in early response to microbial infection against various pathogens by acting as a pattern recognition receptor and by promoting autophagy (PubMed : 16030018, PubMed : 24223991, PubMed : 24583716, PubMed : 25713983). See full target information CD5L

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.